Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CBL-B inhibitor NX-1607

An orally bioavailable, small-molecule inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulatory and antineoplastic activities. Upon oral administration, CBL-B inhibitor NX-1607 targets, binds to and inhibits the activity of CBL-B, which may result in immune activation, the infiltration of natural killer (NK) cells and activated CD8+ T cells in the tumor microenvironment (TME), and the inhibition of tumor growth. CBL-B, an E3 ubiquitin ligase expressed in all leukocyte subsets including T cells and NK cells, is a negative regulator of immune activation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Casitas B-lineage lymphoma B inhibitor NX-1607
Casitas B-lineage lymphoma proto-oncogene-b inhibitor NX-1607
Code name:NX 1607
NX-1607
NX1607
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search